Gyre Therapeutics (GYRE) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 10, 2026, to elect directors, approve executive compensation, ratify the auditor, and approve the conversion of Series B Preferred Stock related to the Cullgen merger.

• The Cullgen merger is an all-stock transaction valued at $300 million, expected to close in Q2 2026, with significant implications for capital structure and management.

• Forward-looking statements highlight risks and uncertainties, especially regarding regulatory approvals and PRC-related business risks.

Voting matters and shareholder proposals

• Proposals include electing two Class II directors, a non-binding say-on-pay vote, auditor ratification, and approval of Series B Preferred Stock conversion.

• Board recommends voting FOR all proposals.

• Shareholders may submit proposals for the 2027 meeting per specified deadlines and requirements.

Board of directors and corporate governance

• Board consists of eight members, divided into three classes with staggered terms; will reduce to seven after the Cullgen merger.

• Board committees include Audit, Compensation, and Nominating, each with defined responsibilities and independent members.

• Controlled company exemption applies due to majority ownership by GNI Japan, allowing certain governance exemptions.

• Code of Business Conduct and Ethics and clawback policy are in place.